Symbicort
E505484
COPD maintenance therapy
asthma maintenance therapy
combination drug
inhaler medication
prescription medication
Symbicort is a prescription inhaler medication that combines a corticosteroid and a long-acting bronchodilator to manage asthma and chronic obstructive pulmonary disease (COPD).
All labels observed (1)
| Label | Occurrences |
|---|---|
| Symbicort canonical | 1 |
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
COPD maintenance therapy
ⓘ
asthma maintenance therapy ⓘ combination drug ⓘ inhaler medication ⓘ prescription medication ⓘ |
| abbreviation | budesonide/formoterol ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| containsComponent |
corticosteroid
ⓘ
long-acting beta2-adrenergic agonist ⓘ |
| hasActiveIngredient |
budesonide
NERFINISHED
ⓘ
formoterol fumarate dihydrate ⓘ |
| hasBrandName | Symbicort NERFINISHED ⓘ |
| hasCommonSideEffect |
cough
ⓘ
headache ⓘ hoarseness ⓘ oral candidiasis ⓘ throat irritation ⓘ |
| hasDosageForm | metered-dose inhaler ⓘ |
| hasGenericName | budesonide and formoterol fumarate dihydrate ⓘ |
| hasManufacturer | AstraZeneca NERFINISHED ⓘ |
| hasPharmacologicClass |
inhaled corticosteroid
ⓘ
long-acting beta2-agonist ⓘ |
| hasRegulatoryStatus | prescription only ⓘ |
| hasRoute | oral inhalation ⓘ |
| hasWarning |
immunosuppression due to corticosteroid component
ⓘ
potential adrenal suppression ⓘ risk of asthma-related death with LABA monotherapy ⓘ |
| improves |
COPD symptom control
ⓘ
asthma symptom control ⓘ lung function ⓘ |
| indicatedFor |
COPD with chronic bronchitis
ⓘ
asthma ⓘ chronic obstructive pulmonary disease ⓘ maintenance treatment of COPD ⓘ maintenance treatment of asthma ⓘ |
| mechanismOfAction |
causes bronchodilation via beta2-adrenergic receptor agonism
ⓘ
reduces airway inflammation via corticosteroid activity ⓘ |
| notIndicatedFor |
relief of acute bronchospasm
ⓘ
rescue treatment for sudden asthma attacks ⓘ |
| reduces |
COPD exacerbations
ⓘ
frequency of asthma exacerbations ⓘ |
| regulates |
airway inflammation
ⓘ
bronchial smooth muscle tone ⓘ |
| requires |
regular daily use for maintenance
ⓘ
rinsing mouth after use to reduce risk of oral thrush ⓘ |
| routeOfAdministration | inhalation ⓘ |
| usedWith | short-acting beta2-agonist rescue inhaler ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.